Abstract
Angiogenesis is the most critical step in the development and progression of malignant tumors. Anti-tumor angiogenesis has become the most promising new strategy for tumor treatment. Rapidly growing tumor cells secrete a variety of vascular growth factors under hypoxia to stimulate tumor angiogenesis. One of the important growth factors is Vascular Endothelial Growth Factor (VEGF). Some small molecule compounds that inhibit VEGFR have been used to treat Tumors. In this study, we evaluated the effectiveness and safety of Apatinib Mesylate tablet in the treatment of advanced solid tumors. We found that Apatinib Mesylate tablet can treat advanced solid tumors.
Highlights
Angiogenesis is the most critical step in the development and pro- *Correspondence to Author: gression of malignant tumors
We found that Apatinib Mesylate tablet can treat ad- Yiguo, WANG Fang, XU Yuanchun
Angiogenesis is the most critical step in the In a recent phase II clinical study, Docetaxel development and progression of malignant combined with ZD6474 was superior to tumors[1] Generally, angiogenesis in the tumor Docetaxel monotherapy 17 Sorafenib secondarea provides nutrients for the tumor growth and line treatment of NSCLC had a disease control takes away its metabolites 2, 3 rate of 59% and a median survival of 6 7 tumor cells are transferred to other parts of body months[18] For second-line treatment of NSCLC
Summary
Angiogenesis is the most critical step in the In a recent phase II clinical study, Docetaxel development and progression of malignant combined with ZD6474 was superior to tumors[1] Generally, angiogenesis in the tumor Docetaxel monotherapy 17 Sorafenib secondarea provides nutrients for the tumor growth and line treatment of NSCLC had a disease control takes away its metabolites 2 , 3 rate of 59% and a median survival of 6 7 tumor cells are transferred to other parts of body months[18] For second-line treatment of NSCLC through the new blood vessels 4 with Sunitinib, effective rate, disease control rate effectively inhibiting angiogenesis in the tumor and median survival time were o9 5%, 52 2%, area could inhibit growth of tumor and reduce the 23 9 months separately[19] occurrence of metastasis[5] Currently, anti-tumor angiogenesis has become the most promising new strategy for tumor treatment[6]. Some small molecule compounds that inhibit VEGFa have been marketed, such as Sunitinib
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call